Jaguar Animal Health, Inc. — 2015 Form 10-K
Reporting period: Fiscal year ended December 31, 2015. This is an annual report; the supplied filing text does not provide a separate fourth-quarter income statement. The company was an early-stage animal-health developer, with Neonorm Calf its first marketed product and Canalevia its lead prescription candidate.
Financial performance and position
| Metric | 2015 | 2014 |
|---|---|---|
| Revenue | $258,381 | None |
| Cost of revenue | $123,457 | None |
| Gross profit / gross margin | Approximately $134,924 / 52% | Not applicable |
| Research and development | $6.48 million | $4.22 million |
| Sales and marketing | $765,091 | None |
| General and administrative | $5.34 million | $4.10 million |
| Operating loss | $12.45 million | $8.32 million |
| Net loss | $16.29 million | $8.61 million |
| Net loss attributable to common stockholders | $16.64 million; $2.70 per share | $9.26 million; $3.24 per share |
- Revenue was Neonorm distributor sales recognized after distributor sell-through; shipments to distributors were not, by themselves, recognized as revenue. The company reported $638,000 of Neonorm Calf shipments to distributors since launch as of March 1, 2016, which is not the same as recognized revenue.
- Operating expenses increased 53% year over year, led by clinical and contract-manufacturing costs. Net loss widened 89%; net interest expense rose to $3.32 million, including substantial debt-discount amortization and other financing costs.
- Cash and cash equivalents were $7.70 million at year-end, with an additional $3.0 million in restricted cash. Operating activities used $14.32 million; investing activities used $3.00 million, primarily restricted cash; financing activities provided $24.17 million. Year-end current assets were $8.45 million versus current liabilities of $3.91 million.
- Long-term debt had a reported net carrying value of $5.80 million, including $1.71 million classified as current. The loan’s contractual rate was 9.9% after the interest-only period, with a disclosed effective rate of 15.0% including discounts and the end-of-term payment. A $150,000 convertible note also remained outstanding.
- Stockholders’ equity was $4.40 million, compared with a deficit of $8.24 million in 2014; accumulated deficit was $25.70 million. The 2015 IPO raised approximately $15.9 million net, and the February 2016 follow-on offering raised approximately $4.1 million net through issuance of 2.0 million shares at $2.50 per share.
Business developments and changes versus 2014
- Canalevia: A 2015 dog proof-of-concept study reported formed stool in 91% of treated dogs versus 50% of placebo recipients. The company submitted major technical sections for conditional approval for chemotherapy-induced diarrhea (CID) to the FDA in August 2015 and began a pivotal field study for acute diarrhea in December 2015.
- Neonorm: Neonorm Calf expanded from a regional U.S. launch to nationwide distribution; Neonorm Foal had a soft launch in December 2015. The company reported positive exploratory foal-study results and began a calf study of a second-generation formulation.
- Equine pipeline: A pilot crofelemer safety study in horses was completed in December 2015. In January 2016, the company announced positive topline proof-of-concept results for SB-300, an investigational horse-ulcer product; these were preliminary development findings, not regulatory approval.
- The company completed its IPO in May 2015, became publicly traded, took on a three-year secured loan, and expanded commercial and development spending. R&D rose 53%, while sales and marketing expense began with product commercialization.
Outlook, risks, and unusual items
- Management expected higher R&D, commercial, and administrative spending in 2016 and continued losses. The filing states that year-end cash was insufficient to fund the operating plan through December 2016; additional capital or partnerships would be needed. The February 2016 offering provided additional proceeds but did not eliminate the disclosed financing and execution risks.
- Management anticipated seeking Canalevia conditional approval for CID during 2016, completing the acute-diarrhea clinical program in the fourth quarter of 2016, and pursuing further animal studies and regulatory discussions. These were expectations, not assurances; FDA approval and clinical success were uncertain.
- The auditor’s report included an explanatory paragraph describing substantial doubt about the company’s ability to continue as a going concern. The financial statements were not adjusted for the outcome of that uncertainty.
- Principal risks include continued cash burn and dependence on new financing; unapproved drug candidates and uncertain study outcomes; limited commercial history; reliance on Napo-licensed intellectual property and third-party manufacturers; supply, regulatory, patent, competition, and product-acceptance risks. The filing reported no pending legal proceedings expected to have a material adverse effect.
- Unusual financing costs materially affected the loss: 2015 interest expense included amortization of debt discounts and a bridge-loan repayment premium. The company also reported a $502,000 adverse change in warrant fair value. In February 2016, it issued 2.0 million shares in a follow-on offering, diluting existing holders.
Important facts for investors to verify
- Current cash runway, use of the February 2016 offering proceeds, and any subsequent financing or liquidity updates.
- FDA progress and pivotal-trial results for Canalevia, including whether the CID conditional-approval pathway and acute-diarrhea timetable remain achievable.
- Neonorm sell-through, repeat orders, gross margins, distributor terms, and whether reported shipments translate into recognized sales and cash collections.
- Debt repayment schedule, restricted-cash requirements, covenants, and the company’s ability to meet future obligations.
- Manufacturing capacity and supply arrangements, and the scope and durability of licensed patents and other intellectual-property rights.